Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Anne J Kugler & Michael L Thiman. (2018) Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data. Diabetes, Metabolic Syndrome and Obesity 11, pages 187-197.
Read now
Read now
André J. Scheen. (2017) Dulaglutide for the treatment of type 2 diabetes. Expert Opinion on Biological Therapy 17:4, pages 485-496.
Read now
Read now
Christian Leporini, Rosanna Piro, Francesco Ursini, Francesca Maida, Caterina Palleria, Franco Arturi, Maria Pavia, Giovambattista De Sarro & Emilio Russo. (2016) Monitoring safety and use of old and new treatment options for type 2 diabetic patients: a two-year (2013–2016) analysis. Expert Opinion on Drug Safety 15:sup2, pages 17-34.
Read now
Read now
Articles from other publishers (5)
Fatemeh Mirzaei, Iraj Khodadadi, Nesrine Majdoub, Seyyed Alireza Vafaei, Heidar Tayebinia & Ebrahim Abbasi. (2022) Role of Glucagon-like Peptide-1 (GLP-1) Agonists in the Management of Diabetic Patients with or without COVID-19. The Open Medicinal Chemistry Journal 16:1.
Crossref
Crossref
Yi Ming Li, Li Hui Zhang, Xue Jun Li, Bin Zhang, Jia Ning Hou & Nan Wei Tong. (2020) Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1. Diabetes Therapy 11:5, pages 1077-1090.
Crossref
Crossref
Yu Hong Chen, Chien-Ning Huang, Young Min Cho, Pengfei Li, Liqun Gu, Feng Wang, Jun Yang & Wei Qing Wang. (2018) Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial. Diabetes, Obesity and Metabolism 20:9, pages 2121-2130.
Crossref
Crossref
Keiji Hirai, Shigeki Imamura, Susumu Ookawara, Aizan Hirai & Yoshiyuki Morishita. (2017) Effects of Once-Weekly Dulaglutide on Glycemic Control and Renal Function in Patients with Advanced-Stage Diabetic Nephropathy. Nephro-Urology Monthly 9:5.
Crossref
Crossref
Yoshio Sumida, Yuya Seko & Masashi Yoneda. (2017) Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatology Research 47:4, pages 266-280.
Crossref
Crossref